Upon payment of all the taxes and contributions, the Enterprise realised a net profit in the amount of 117 mln. rub., the larger half of which will be used in 2018 as the source of capital contributions funding.
The profit was realised despite the shut-down of two production facilities in 2017 for reconstruction in order to create the present-day production of injectables and transdermal therapeutic systems, and transmucosal films corresponding to GMP international standard.
It is planned to obtain in 2018 the net profit accounted for the reconstructed manufacture products in the amount of at least 200 mln. roubles.
At year-end, the Enterprise put into operation a number of articles of fixed assets used in the manufacturing activities. The innovations size amounted to 105 mln. roubles.
The annual increase in the net assets as Enterprise’s own sources of funds made 123 mln. roubles and totalled to 2458 mln. roubles. The growth in the efficacy of using the labour force increased the work performance by 14%.
The Enterprise has the high level of financial stability, ensures the liquidity of all current and future obligations, follows the path of innovation development, improvement in product competitiveness and quality, and is oriented to new areas of activities.
Comment type is not specified in the component properties.